Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3:e253238.
doi: 10.1001/jamasurg.2025.3238. Online ahead of print.

Acute Normovolemic Hemodilution in Adult Cardiac Surgery

Kenichi A Tanaka  1 , Kenneth E Stewart  1   2 , Kofi B Vandyck  1 , Harold M Burkhart  2 , Tabitha Garwe  2   3 , Miklos D Kertai  4 , Amir L Butt  1 , Michael A Mazzeffi  5
Affiliations

Acute Normovolemic Hemodilution in Adult Cardiac Surgery

Kenichi A Tanaka et al. JAMA Surg. .

Abstract

Importance: Acute normovolemic hemodilution (ANH) is a well-known blood conservation technique, yet its adoption in the US remains low (<20%), and cardiac surgery remains the largest consumer of blood components. Increasing vulnerabilities in the US blood supply underscore the need to reassess ANH effectiveness in blood conservation.

Objective: To evaluate ANH use in perioperative transfusion and blood component use in patients undergoing surgery with cardiopulmonary bypass (CPB).

Design, setting, and participants: A retrospective propensity-score matched cohort study using data from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (version 4.20.2). The study included adult patients (≥18 years) undergoing coronary artery bypass grafting (CABG) and/or valve surgery with CPB (July 2020 to September 2023).

Exposure: The primary exposure was ANH, defined as any recorded use/volume in the STS database.

Main outcome and measures: The primary outcome was intraoperative or postoperative transfusion of any blood component. The volume-dependent ANH effect estimate was also assessed using a cutoff value of 650 mL. Secondary outcomes included the total number of transfused red blood cells (RBC) and non-RBC components (platelets, plasma, and cryoprecipitate); bleeding reexplorations; length of stay in the intensive care unit; and estimates for blood acquisition and activity-based costs.

Results: Among 16 795 patients (mean [SD] age, 65.3 [10.5] years; 12 114 male [72.1%]), ANH was reported in 2463 cases (14.7%). Patients receiving ANH had a significantly lower preoperative anemia rate and higher baseline hematocrit (mean difference: 2.5%; 95% CI, 2.3-2.7; P < .001). After propensity score matching (n = 2282 pairs), transfusion rates were significantly lower in the ANH group (31.2% vs 36.4%; P < .001). ANH was associated with 27% lower odds of any transfusion (odds ratio, 0.73; 95% CI, 0.60-0.89). High-volume ANH (≥650 mL) further reduced the odds of transfusion by 47% to 64% for both RBC and non-RBC components. The cumulative number of transfused erythrocyte and platelet units was 167 and 295 units lower, respectively, in the ANH group compared with the control group, with lower estimates for both acquisition and activity-based costs.

Conclusions and relevance: In this study, a volume-dependent association was found between ANH and reduced RBC and non-RBC transfusion rates in patients undergoing cardiac surgery. Despite being safe and cost-effective, ANH remains underused as a blood conservation strategy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tanaka reported grants from Octapharma Clinical Trial, personal fees from Octapharma Consultation, personal fees from CSL Behring Consultation, grants from CellPhire Clinical Trial, grants from HikariDx Clinical Trial, and grants from Grifols Grant support outside the submitted work. Dr Mazzeffi reported grants from Takeda, personal fees from Octapharma, personal fees from Hemosonics, and personal fees from Novo Nordisk outside the submitted work. No other disclosures were reported.

Comment in

  • doi: 10.1001/jamasurg.2025.3245

References

    1. Vervoort D, Lee G, Ghandour H, et al. Global cardiac surgical volume and gaps: trends, targets, and way forward. Ann Thorac Surg Short Rep. 2023;2(2):320-324. doi: 10.1016/j.atssr.2023.11.019 - DOI - PMC - PubMed
    1. Hensley NB, Cho BC, Visagie M, Lester LC, Abernathy JH III, Frank SM. How do I audit intraoperative blood component utilization in cardiac surgery? Transfusion. 2019;59(10):3058-3064. doi: 10.1111/trf.15399 - DOI - PubMed
    1. Bartoszko J, Martinez-Perez S, Callum J, Karkouti K; FIBRES Study Investigators . Impact of cardiopulmonary bypass duration on efficacy of fibrinogen replacement with cryoprecipitate compared with fibrinogen concentrate: a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) randomised controlled trial. Br J Anaesth. 2022;129(3):294-307. doi: 10.1016/j.bja.2022.05.012 - DOI - PubMed
    1. Myles PS, Smith JA, Forbes A, et al. ; ATACAS Investigators of the ANZCA Clinical Trials Network . Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376(2):136-148. doi: 10.1056/NEJMoa1606424 - DOI - PubMed
    1. Pandey S, Belanger GA, Rajbhandary S, et al. A survey of US hospitals on platelet inventory management, transfusion practice, and platelet availability. Transfusion. 2021;61(9):2611-2620. doi: 10.1111/trf.16561 - DOI - PubMed

LinkOut - more resources